Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the herbal combination PRO 160/120 significantly improved nocturnal voiding frequency in patients with moderate-to-severe LUTS/BPH compared to placebo, with similar effectiveness to tamsulosin and finasteride.

This study examined the dementia risk in patients with benign prostatic hyperplasia using alpha-blockers and 5-alpha reductase inhibitors, finding no significant association between these medications and increased dementia risk compared to no treatment, but noted higher risk probabilities for certain 5ARIs.

This article discusses the effectiveness of adrenal cortex compounds E and F in treating connective tissue disorders like rheumatoid arthritis and lupus erythematosus, but it reports no new clinical results.

This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients.

This article discusses drug repurposing as a strategy to find new uses for existing medications, highlighting its potential benefits like faster development and lower costs, while also addressing challenges such as drug specificity, ethical concerns, and regulatory issues.

This study introduced the KRDQN predictive framework, which outperformed existing methods in predicting adverse drug reactions and provided interpretable insights into drug mechanisms, aiding pharmacovigilance and clinical decision-making.

This study observed that proretinal nanoparticles delivered significantly higher concentrations of retinal to the stratum corneum and hair follicles compared to non-particulate forms, potentially improving topical retinoid therapy.

In this study, 5-α reductase inhibitors were not significantly linked to increased rhabdomyolysis risk, but they may raise the risk of myopathy and myositis in men aged 66 and older.

This review found that 5α‐reductase inhibitors were associated with slightly increased rates of decreased libido, erectile and ejaculatory dysfunction, gynecomastia, and mood disorders compared to placebo, though their long-term effects remain unclear.

This abstract reviews 5α-reductase inhibitors and their side effects in patients with sexual dysfunction but reports no new findings.

In this study, researchers observed that acute stress increased levels of the enzyme 5αR2 in the medial prefrontal cortex of male rats, affecting stress reactivity, but this effect was not seen in females.

Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.

This article discusses the limitations of relying on literature and regulatory documents for pharmaceutical evidence, proposing public health decisions be based on independent trials like those by the Mario Negri Institute.

The authors concluded that finasteride treatment inhibits hippocampal neurogenesis in mice, potentially impacting emotional behaviors and contributing to the pathophysiology of affective disorders.

Finasteride can help with hair loss but may cause mental health issues like depression and anxiety.

This study found that proretinal nanoparticles, applied topically, are safe and effective for penetration into hair follicles, enhancing retinoid biological activity in the skin while reducing irritation compared to conventional retinal formulations.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.

This study found that switching patients with glaucoma or ocular hypertension from benzalkonium chloride-latanoprost to preservative-free latanoprost maintained intraocular pressure control and improved tolerability, potentially enhancing treatment adherence and quality of life.

This study reported that oral JAK inhibitors, tofacitinib and ruxolitinib, may effectively promote hair regrowth in alopecia areata patients, though ruxolitinib had fewer adverse events compared to tofacitinib.

This study found that oral tofacitinib significantly reduced alopecia severity and improved quality of life over 12 months for children with moderate to severe alopecia areata, though the authors recommend more research due to the small sample size and absence of a control group.

Scale created to measure hair loss in men and women; MK-386 reduces acne; Niaspan treats dyslipidemia; minoxidil increases heart rate.

This study found that finasteride reduced sperm count, motility, and levels of reproductive hormones, indicating negative effects on fertility in albino male rats.

This study found that adolescent men in Ireland are more likely to prefer keeping a baby over abortion in a hypothetical unplanned pregnancy, influenced by their anticipated regret and perceived familial attitudes.

This study suggests that setipiprant's inhibitory effect on aldose reductase may contribute to its anti-inflammatory properties, adding a possible mechanism beyond its known action on the prostaglandin D2 receptor.

In this study, SMR-2 and SMR-6, retinoid analogs, were found to be approximately 100 times more toxic than retinoic acid in male mice, primarily affecting skin, immune, and reproductive systems.

In this single-blind clinical trial, adding 1% topical cetirizine to 5% topical minoxidil for 16 weeks did not show improved hair growth outcomes in patients with androgenetic alopecia compared to minoxidil alone, although patient satisfaction was higher with the addition of cetirizine.

This review concludes that the global literature supports the efficacy and safety of lipidosterolic extract of Serenoa repens in treating lower urinary tract symptoms, comparable to alpha-blockers and 5α-reductase inhibitors.

This study constructed a model to predict finasteride's inhibitory activity on 5α-reductase type 2 and calculated that a 1 μM plasma concentration, after 50 mg administration, matches prostate inhibition levels.

This study found that blocking corticotropin-releasing factor receptors with astressin-B promoted hair regrowth and prevented alopecia in a mouse model of stress-induced hair loss.

This review suggests a causal relationship between finasteride, used for hair loss, and persistent neuropsychiatric side effects like depression, citing evidence that fulfills key causality criteria and calls for cautious use along with strengthened regulatory oversight.